News

Publication of 2016 Registration Document

Paris (France), April 25, 2017 – 5.45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced the publication of the Company’s 2016 Registration Document. The 2016 Registration Document, filed with the French Market Authorities (Autorité des Marchés…read more →

Clinigen and Onxeo initiate Managed Access programme for belinostat in Europe for patients with peripheral T-cell lymphoma (PTCL)

Paris, April 24, 2017 – 18 :30 CEST. Clinigen Group plc’s (AIM: CLIN, ‘Clinigen’ or the ‘Group’) Idis Managed Access (MA) division and Onxeo S.A (Euronext Paris, Nasdaq Copenhagen: ONXEO, ‘Onxeo’), have agreed to launch a Managed Access programme for belinostat (Beleodaq®) in Europe. Belinostat is for use in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). PTCL is a…read more →

Onxeo receives the EnterNext Tech 40 Label

Onxeo is admitted to the “Tech 40” index, which incorporates 40 outstanding small and midcap Tech companies listed on the various Euronext markets in Europe Paris, April 20, 2017 – 8:30 pm CEST. Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology,…read more →

Onxeo to Present Data Supporting Three Key Orphan Oncology Assets at AACR Annual Meeting

Preclinical studies of AsiDNA™, Livatag® and Beleodaq® Paris (France), March 21, 2017 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, announced today the presentation of data from three studies supporting the company’s primary drug candidates in…read more →

Full-year 2016 Results and Outlook for 2017

Reinforcement of Onxeo’s strategic positioning in the development of innovative oncology treatments Acquisition of DNA Therapeutics and the AsiDNATM product, a first-in-class candidate in the new area of preventing tumor cells from repairing their DNA Enrolment for the phase III Livatag® study in advanced primary liver cancer completed on schedule to deliver preliminary results mid-2017 Cash and cash equivalents of…read more →

Onxeo Appoints Seasoned Executives to Accelerate Preclinical and Clinical Development

Françoise Bono, PhD, Named Chief Scientific Officer to Lead Preclinical Activities Olivier de Beaumont, MD, MBA, Appointed Chief Medical Officer to Lead Clinical Development and Operations, Medical and Regulatory Affairs Paris (France), March 1, 2017 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment…read more →

Onxeo receives USPTO Notice of Allowance for a new AsiDNA™-related patent, expanding its IP protection in the U.S.

New patent expands Onxeo’s intellectual property to a large family of compounds related to AsiDNA™  Paris (France), February 13, 2017 – 18:00 CET – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced that the U.S. Patent and Trademark…read more →

Information on ReLive Trial Design and Role of its Data Safety and Monitoring Board

Paris (France), February 8, 2017 – 8.30 am CET – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, wishes to clarify information regarding the ReLive trial design and conduct and, in particular, the role of its Data Safety and Monitoring…read more →

Radiotherapy, immunotherapy and DNA repair inhibitors: a winning combination towards the oncology of the future

The Institut Curie and Onxeo join forces in this ambitious project that will benefit cancer patients Paris (France), Copenhagen (Denmark), January 31, 2017 – 08:30 am CET – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, and the Institut Curie, a…read more →

Onxeo Completes Enrollment in Phase III Study of Livatag® for the Treatment of Hepatocellular Carcinoma

Milestone completion in line with expected preliminary outcomes mid-2017  Paris (France), Copenhagen (Denmark), January 24, 2017 – 18:30 CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced the completion of enrollment in ReLive, the international Phase III clinical…read more →

Meet the Onxeo Team during the 2017 J.P. Morgan Healthcare Conference

January 9-12, 2017 in San Francisco, CA  In 2016, Onxeo has achieved a number of significant milestones, positioning the Company for success in 2017 and beyond. With a robust pipeline focused on addressing unmet medical needs in the treatment of rare cancers, Onxeo is poised to become the leader in orphan oncology. Onxeo has a promising therapeutic pipeline with multiple…read more →

Onxeo to Attend Two French Investor Conferences in January

Oddo Investor Forum, January 5-6, 2017 in Lyon Invest Securities BioMed Event, January 26, 2017 in Paris  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced that the Company’s management will attend the Oddo Investor Forum,…read more →

The French Academy of Sciences Awards the Guy Lazorthes Prize to Doctor Marie Dutreix for Her Innovative Research on the Dbait Technology

Since the acquisition of the Dbait technology last February, Onxeo has launched an ambitious clinical development program for AsiDNA™, a first-in-class product derived directly from this technology Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced that…read more →

Onxeo Announces Its Financial Calendar for 2017

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced its financial calendar for 2017: March 7, 2017                                      Full-year 2016 consolidated accounts  April 26, 2017                                      General shareholders’ meeting (to be convened in Paris) April 27,…read more →

Onxeo Strengthens AsiDNA™ Patent Protection in Europe

Composition of matter patent to be granted in Europe covering AsiDNA™ and more precisely the part related to its DNA sequence until 2027 Any product including this specific DNA sequence will be within the scope of this patent AsiDNA™’s intellectual property will now be protected by 8 complementary patent families worldwide  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen:…read more →